TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive ACS to Purchase $1.5 Million In animal Interferon, Offer it for Laboratory Studies July 13, 1984
TCL Archive St. Jude Children’s Research Hospital Wins NCI Designation As Comprehensive. May 16, 2008